SWORD Data Sharpen Commercial Appetite For ViiV’s Juluca, But Is It Too Little Too Late?
Executive Summary
ViiV Healthcare has published results from the first long-term Phase III study for switching from a three-drug combination, to an oral two-drug combination. It disproves resistance and safety fears that have hampered prescriber comfort, however, it may have to dampen its sales ambitions when ViiV’s soon-to-be-approved combo Tivicay/Epivir comes to market.
You may also be interested in...
ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"
The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist, ViiV Healthcare, suggests a shift away from three-drug regimens for HIV/AIDS could be gathering pace.
ViiV Two-Drug HIV Pill Juluca Close To Europe Okay
The likely EMA approval of Juluca challenges the traditional HIV treatment paradigm of a three-drug regimen, with the single tablet, two-drug regimen offering the same efficacy as well as reduced toxicity and greater convenience.
ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow
Pricing of $31,000 annually for GSK/J&J's single-tablet, two-drug HIV regimen Juluca (dolutegravir/rilpivirine) is on par with marketed fixed-dose combinations that include integrase inhibitors.